LSD Microdosing Shows Acute Mood Boosts in Small Depression Pilot Study

Participants reported higher creativity, energy, and social connectedness on days they took the microdose, with increased happiness on the first two days and reduced irritability two days later. Blood samples showed peak plasma concentration just over one hour after sublingual administration, and perceived effects remained stable across fifteen home doses, indicating no rapid tolerance or sensitization.

Psypost

The eight-week Phase 2a trial enrolled 19 adults diagnosed with major depressive disorder (MDD). An initial laboratory session delivered an exact 8 µg sublingual dose of liquid LSD. For the remaining weeks, participants self-administered the drug twice weekly at 4–20 µg, totaling fifteen home doses. Most participants were male, many were concurrently taking standard antidepressants, and daily monitoring was conducted via a customized smartphone app.

Psypost

Daily surveys used visual analog scales to rate creativity, energy, connectedness, happiness, irritability, and jitteriness. Acute mood improvements aligned with dosing days, while the three-day depression questionnaire showed no statistically significant change. A formal clinical interview at trial end recorded an average 60 % reduction in depression severity across the cohort.

Psypost

Pharmacokinetic analysis confirmed peak blood levels around one hour post-dose. Participants who metabolized LSD faster (lower peak concentrations) tended to increase their home dose over time, whereas slower metabolizers maintained lower doses. The stability of self-reported effect strength suggests minimal tolerance development over the study period.

Psypost

The research team emphasized that the trial demonstrates the feasibility and safety of self-managed LSD microdosing with remote monitoring. Authors—Dimitri Daldegan-Bueno, Carina Joy Donegan, Rachael Sumner, Anna Forsyth, Soo Hee Jeong, William Evans, Malak Alshakhouri, Robin J. Murphy, Lisa Reynolds, Nicholas Hoeh, Nathan Allen, Frederick Sundram, David B. Menkes, and Suresh Muthukumaraswamy—characterized the findings as exploratory and called for randomized, double-blind studies to confirm efficacy.

Psypost

Independent reviewers noted the uncontrolled, open-label design, which allows participant expectations to influence outcomes (placebo effect). The small, predominantly male sample and concurrent antidepressant use limit generalizability. Absence of a placebo arm prevents isolation of LSD’s pharmacological impact from trial participation effects.

Psypost

A key discrepancy emerged: daily depression scores did not show significant improvement, whereas the end-of-trial interview indicated a 60 % severity drop. Researchers attributed this to overlapping questionnaire windows that obscured dose-specific effects. Additional gaps include lack of long-term follow-up and limited demographic diversity.

Psypost

The study supports the hypothesis that low-dose LSD can acutely modulate serotonin receptors, potentially enhancing brain signaling flexibility in MDD. If replicated in controlled trials, microdosing could complement existing therapies, offering a rapid-acting adjunctive option.

Psypost

Planned Phase 2b investigations will employ randomized, double-blind protocols with larger, more diverse cohorts. These trials aim to compare LSD microdosing against placebo, assess sustained efficacy, monitor safety over extended periods, and clarify the role of microdosing within standard depression treatment algorithms.

Psypost